Resources Repository
-
ArticlePublication 2015Valuing Regulations Affecting Addictive or Habitual Goods
The analysis of regulations affecting addictive or habitual goods has drawn considerable controversy. Some studies …
The analysis of regulations affecting addictive or habitual goods has drawn considerable controversy. Some studies have suggested that such regulations have only small welfare benefits, as consumers value these goods despite health benefits from quitting, while other studies suggest that information or behavioral problems make existing consumption decisions a poor guide to welfare evaluation. This analysis examines potential utility offsets to health benefits of regulations affecting addictive or habitual goods theoretically and empirically. The paper…
Preferences/Values | Benefit-Cost Analysis | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Culture/Society | Economics/Finance | Health/Medicine | North America -
ReviewPublication 2015Population Health: Behavioral and Social Science Insights
This book comprises 23 chapters focused on what the effects of various behavioral and social factors …
This book comprises 23 chapters focused on what the effects of various behavioral and social factors on longevity, disability and illness, and quality of life, primarily at the population level. Factors such as access to health care, educational attainment, nutrition, physical activity, use of tobacco products, and non-communicable diseases are considered, along with many other determinants of health and longevity. Of particular interest for health decision scientists are the following chapters: In Section 4: The Science…
Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global | North America | Europe -
ArticlePublication 2015Cost-Effectiveness of First-Line Antiretroviral Therapy for HIV-Infected African Children Less Than 3 Years of Age
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine …
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine with second-line lopinavir/ritonavir, and first-line lopinavir/ritonavir with second-line nevirapine) for HIV-infected children less than 3 years of age in Africa, using the Cost-Effectiveness of Preventing AIDS Complications- Pediatric model and data obtained from the International Maternal, Pediatric, and Adolescent Clinical Trial P1060 trial. Results demonstrated that both ART regimens were very cost-effective compared to no ART. First-line lopinavir/ritonavir led to longer…
Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Health/Medicine | Sub-Saharan Africa -
ReviewPublication 2015Decision-Analytic Modeling Studies of Multiple Myeloma
This review provides an overview of decision-analytic models evaluating different treatment strategies for multiple myeloma …
This review provides an overview of decision-analytic models evaluating different treatment strategies for multiple myeloma and is based on a systematic literature search to identify studies evaluating treatment strategies using mathematical decision-analytic models. Studies were included that assessed relevant clinical endpoints, and summarized methodological characteristics (e.g., modeling approaches, simulation techniques, health outcomes, perspectives). Eleven decision-analytic modeling studies met inclusion criteria. Five different modeling approaches were adopted: decision-tree modeling, Markov state-transition modeling, discrete event simulation, partitioned-survival analysis and…
Microsimulation | Mathematical Models | State-Transition | Dynamic Simulation | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
Tutorial/PrimerPublication, Teaching Resource 2015White Paper: Retrospective Benefit-Cost Analysis
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote …
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote understanding of the impacts after a policy is implemented. Serving as a brief primer, the authors propose that analysis can be useful for identifying needed reforms as well as in improving the conduct of future prospective analyses. The major challenges relate to estimating what would have occurred in the absence of the policy and separating the effects of the policy…
Priority Setting/Ethics | Benefit-Cost Analysis | Social Determinants | Environmental Health | Policy/Regulation | Culture/Society | Economics/Finance | Government/Law | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Policy Translation -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2015Salt Reduction Policy in South Africa: Extended Cost-Effectiveness Analysis
This paper is an extended cost-effectiveness analysis to model the potential health and economic impacts of …
This paper is an extended cost-effectiveness analysis to model the potential health and economic impacts of a salt reduction policy in South Africa. The authors used surveys and epidemiologic studies to estimate reductions in CVD resulting from lower salt intake. They calculated the average out-of-pocket (OOP) cost of CVD care and estimated the reduction in OOP expenditures and government subsidies due to the policy. They also estimated the costs of policy implementation and financial risk protection (FRP) benefits. The…
Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine | Sub-Saharan Africa -
Tutorial/PrimerPublication, Teaching Resource 2015Educational Review of the Statistical Issues in Utility Data for CEA
The aim of cost-utility analysis is to support decision making in healthcare by providing a …
The aim of cost-utility analysis is to support decision making in healthcare by providing a standardized mechanism for comparing resource use and health outcomes across programmes of work. The focus of this review is the denominator of the cost-utility analysis, specifically the methodology and statistical challenges associated with calculating QALYs from patient-level data collected as part of a trial. The authors provide a brief description of the most common questionnaire used to calculate patient level…
Preferences/Values | Health Outcomes | Cost-Effectiveness Analysis | Health/Medicine